Workflow
Bellevue Life Sciences Acquisition (BLAC)
icon
Search documents
Bellevue Life Sciences Acquisition (BLAC) - 2023 Q1 - Quarterly Report
2023-05-21 16:00
The fair value of certain of the Company's assets and liabilities, which qualify as financial instruments under ASC 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of March 31, 2023 due to the short maturities of such instruments. Concentration of Credit Risk Warran ...
Bellevue Life Sciences Acquisition (BLAC) - 2022 Q4 - Annual Report
2023-03-30 16:00
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentivebased compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D1(b ...